NCT00324961View on ClinicalTrials.gov

Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B

PHASE4CompletedINTERVENTIONAL
Enrollment

533

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Chronic Hepatitis B
Interventions
DRUG

adefovir dipivoxil tablets

adefovir dipivoxil once daily 10 mg orally

Trial Locations (18)

100011

GSK Investigational Site, Beijing

100044

GSK Investigational Site, Beijing

100050

GSK Investigational Site, Beijing

130021

GSK Investigational Site, Changchun

200001

GSK Investigational Site, Shanghai

200003

GSK Investigational Site, Shanghai

200025

GSK Investigational Site, Shanghai

200040

GSK Investigational Site, Shanghai

200433

GSK Investigational Site, Shanghai

210029

GSK Investigational Site, Nanjing

250021

GSK Investigational Site, Jinan

310003

GSK Investigational Site, Hangzhou

400038

GSK Investigational Site, Chongqing

GSK Investigational Site, Chongquin

410008

GSK Investigational Site, Changsha

430030

GSK Investigational Site, Wuhan

510515

GSK Investigational Site, Guangzhou

510630

GSK Investigational Site, Guangzhou

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00324961 - Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B | Biotech Hunter | Biotech Hunter